This study focuses on patients with moderate to severe ulcerative colitis, a chronic inflammatory condition affecting the large intestine. The research evaluates a new medication called SAR442970, which is given as a solution for injection under the skin (subcutaneous injection). The purpose is to determine if different doses of this medication can help patients achieve remission of their disease.
During the study, participants will receive either SAR442970 or placebo for 16 weeks, followed by a longer treatment period of up to 52 weeks. The medication is administered through injections under the skin, with doses up to 300 milligrams. Patients’ response to treatment will be monitored through various examinations of the intestine and assessment of disease symptoms.
The study will look at how well the treatment works by measuring improvements in intestinal inflammation, bowel movements, and overall disease activity. The research will also track any side effects that may occur during the treatment period. Throughout the study, researchers will monitor the levels of the medication in patients’ blood and check for the development of antibodies against the treatment.
Czechia 
France 
Germany 
Hungary 
Poland 
Spain 
